Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
0.81% $1.250
America/New_York / 23 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 321.66 mill |
EPS: | -0.260 |
P/E: | -4.81 |
Earnings Date: | May 03, 2024 |
SharesOutstanding: | 257.33 mill |
Avg Daily Volume: | 9.15 mill |
RATING 2024-04-23 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | |
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.81 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.82x |
Company: PE -4.81 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.0388 (-96.90%) $-1.211 |
Date: 2024-04-24 |
Expected Trading Range (DAY) |
---|
$ 1.052 - 1.448 ( +/- 15.84%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-16 | Qamar Huma | Buy | 308 465 | Option (Right to Buy) |
2024-03-18 | Qamar Huma | Sell | 0 | Common Stock |
2023-09-15 | Breininger Michael | Buy | 0 | |
2024-01-03 | Musunuri Shankar | Sell | 180 204 | Common Stock |
2024-01-03 | Upadhyay Arun | Sell | 41 633 | Common Stock |
INSIDER POWER |
---|
65.13 |
Last 96 transactions |
Buy: 10 862 012 | Sell: 2 992 475 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.250 (0.81% ) |
Volume | 6.85 mill |
Avg. Vol. | 9.15 mill |
% of Avg. Vol | 74.89 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $0.527 | N/A | Active |
---|
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.